Mannkind Corp (MNKD) 6.33 $MNKD
Higher Expenses Widen MannKind's Q1 Loss by 27%
Sean Williams, The Motley Fool - Motley Fool - Mon May 12, 4:20PM CDT
Clinical-stage biopharmaceutical company MannKind reported its first-quarter results before the opening bell this morning, pointing to higher spending ahead of its all-important PDUFA decision for experimental inhaled diabetes drug Afrezza on...
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
MannKind Corporation Reports 2014 First Quarter Financial Results
GlobeNewswire - Mon May 12, 8:15AM CDT
MannKind Corporation (Nasdaq:MNKD) today reported financial results for the first quarter ended March 31, 2014.
MannKind Corporation Earnings: Are Better Times Ahead?
Dan Caplinger, The Motley Fool - Motley Fool - Sat May 10, 2:15PM CDT
On Monday, MannKind will release its quarterly report, and investors don't expect any immediate positive results from the clinical-stage biotechnology company. The company has been waiting for a long time for FDA approval of its Afrezza inhaled...
The Fool Looks Ahead
Rick Munarriz, The Motley Fool - Motley Fool - Sat May 10, 11:30AM CDT
There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come. Monday The market kicks off the new trading week with MannKind reporting quarterly results after the market close. MannKind's been...
Insider Buying On The Rise At These 5 Stocks With Earnings Next Week
at The Street - Thu May 08, 3:33PM CDT
James Dennin, Kapitall: Stocks are rebounding today on strong earnings. We looked for insider buying spikes among stocks with earnings [...]
MannKind to Present at Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Wed May 07, 4:48PM CDT
MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014 at 8:40 am Pacific Time at the Encore at the Wynn Hotel in Las Vegas, Nevada.
Biotech 101: Valuing Binary Events
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:18PM CDT
Binary events are the lifeblood of investing in biotech companies. A clinical trial result or Food and Drug Administration decision can send the company's value up or down considerably. And not necessarily the same amount in either direction; the...
MannKind Corporation to Hold 2014 First Quarter Financial Results Conference Call on May 12, 2014
GlobeNewswire - Mon May 05, 8:42AM CDT
MannKind Corporation (Nasdaq:MNKD) will release its 2014 first quarter financial results on Monday, May 12, 2014 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 5:00 PM (Eastern Time) on May 12, 2014.
Insider Buying Is On The Rise At These 7 Mid-cap Stocks
at The Street - Wed Apr 30, 4:11PM CDT
James Dennin, Kaptiall: Insider buying is on the rise at these 7 mid-cap stocks. Are their employees right to be [...]
Active Stocks Technical Review -- Research on AES Corp., Baidu, Hertz Global Holdings, and MannKind
PR Newswire - Wed Apr 30, 12:01PM CDT
The markets on Tuesday, April 29, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,535.37, up 0.53% and the NASDAQ Composite closed at 4,103.54, up 0.72%. The S&P 500 edged 0.48% higher, to finish the day at 1,878.33. The gains were broad based as eight out of ten sectors finished on a higher note. During the session, gains in the Financials, Information Technology and Materials sectors positively impacted the broader market, while some retraction came in from Utilities and Consumer Staples sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include AES Corp. (NYSE: AES), Baidu Inc. (NASDAQ: BIDU), Hertz Global Holdings Inc. (NYSE: HTZ) and MannKind Corp. (NASDAQ: MNKD). Free technical research on AES, BIDU, HTZ and MNKD can be downloaded upon signing up at:
Biotech IPOs Hit the Wall
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
While many investors ignore biotechs that have just gone public, waiting for them to mature, you should still keep an eye on the state of the IPO market, since it's a barometer for the risk investors are willing to take with established public...
Abattis Bioceuticals Corp. Enters Into Share Agreement with Experion
ACCESSWIRE - Thu Apr 17, 9:00AM CDT
On Apr. 16, Abattis Bioceuticals Corp. (OTCPINK: ATTBF) share volume soared, with 1,166,632 changing hands, significantly higher than its three-month average
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC"
, a Chicago-based institutional investor for up to $40 million.
Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
Look for Shares of MannKind to Potentially Rebound after Yesterday's 1.87% Sell Off
Comtex SmarTrend(R) - Mon Apr 14, 5:31PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.15 to a high of $6.58. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $6.31 on volume of 9.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MannKind's Overly-Optimisitic Investors
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:47PM CDT
Last week, MannKind announced that the Food and Drug Administration was delaying a decision about whether to approve its inhaled insulin Afezza by three months. Investors seemed surprised, with shares falling 8% on Monday, although it made all...
Critical Alerts For Walt Disney, Walgreen, BioMarin Pharmaceuticals, Canadian Solar, and MannKind Released By InvestorsObserver
PR Newswire - Mon Apr 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DIS, WAG, BMRN, CSIQ, and MNKD.
Higher Expenses Widen MannKind's Q1 Loss by 27%
Sean Williams, The Motley Fool - Motley Fool - Mon May 12, 4:20PM CDT
Clinical-stage biopharmaceutical company MannKind reported its first-quarter results before the opening bell this morning, pointing to higher spending ahead of its all-important PDUFA decision for experimental inhaled diabetes drug Afrezza on...
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
MannKind Corporation Reports 2014 First Quarter Financial Results
GlobeNewswire - Mon May 12, 8:15AM CDT
MannKind Corporation (Nasdaq:MNKD) today reported financial results for the first quarter ended March 31, 2014.
MannKind Corporation Earnings: Are Better Times Ahead?
Dan Caplinger, The Motley Fool - Motley Fool - Sat May 10, 2:15PM CDT
On Monday, MannKind will release its quarterly report, and investors don't expect any immediate positive results from the clinical-stage biotechnology company. The company has been waiting for a long time for FDA approval of its Afrezza inhaled...
The Fool Looks Ahead
Rick Munarriz, The Motley Fool - Motley Fool - Sat May 10, 11:30AM CDT
There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come. Monday The market kicks off the new trading week with MannKind reporting quarterly results after the market close. MannKind's been...
Insider Buying On The Rise At These 5 Stocks With Earnings Next Week
at The Street - Thu May 08, 3:33PM CDT
James Dennin, Kapitall: Stocks are rebounding today on strong earnings. We looked for insider buying spikes among stocks with earnings [...]
MannKind to Present at Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Wed May 07, 4:48PM CDT
MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014 at 8:40 am Pacific Time at the Encore at the Wynn Hotel in Las Vegas, Nevada.
Biotech 101: Valuing Binary Events
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:18PM CDT
Binary events are the lifeblood of investing in biotech companies. A clinical trial result or Food and Drug Administration decision can send the company's value up or down considerably. And not necessarily the same amount in either direction; the...
MannKind Corporation to Hold 2014 First Quarter Financial Results Conference Call on May 12, 2014
GlobeNewswire - Mon May 05, 8:42AM CDT
MannKind Corporation (Nasdaq:MNKD) will release its 2014 first quarter financial results on Monday, May 12, 2014 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 5:00 PM (Eastern Time) on May 12, 2014.
Insider Buying Is On The Rise At These 7 Mid-cap Stocks
at The Street - Wed Apr 30, 4:11PM CDT
James Dennin, Kaptiall: Insider buying is on the rise at these 7 mid-cap stocks. Are their employees right to be [...]
Active Stocks Technical Review -- Research on AES Corp., Baidu, Hertz Global Holdings, and MannKind
PR Newswire - Wed Apr 30, 12:01PM CDT
The markets on Tuesday, April 29, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,535.37, up 0.53% and the NASDAQ Composite closed at 4,103.54, up 0.72%. The S&P 500 edged 0.48% higher, to finish the day at 1,878.33. The gains were broad based as eight out of ten sectors finished on a higher note. During the session, gains in the Financials, Information Technology and Materials sectors positively impacted the broader market, while some retraction came in from Utilities and Consumer Staples sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include AES Corp. (NYSE: AES), Baidu Inc. (NASDAQ: BIDU), Hertz Global Holdings Inc. (NYSE: HTZ) and MannKind Corp. (NASDAQ: MNKD). Free technical research on AES, BIDU, HTZ and MNKD can be downloaded upon signing up at:
Biotech IPOs Hit the Wall
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
While many investors ignore biotechs that have just gone public, waiting for them to mature, you should still keep an eye on the state of the IPO market, since it's a barometer for the risk investors are willing to take with established public...
Abattis Bioceuticals Corp. Enters Into Share Agreement with Experion
ACCESSWIRE - Thu Apr 17, 9:00AM CDT
On Apr. 16, Abattis Bioceuticals Corp. (OTCPINK: ATTBF) share volume soared, with 1,166,632 changing hands, significantly higher than its three-month average
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC"
, a Chicago-based institutional investor for up to $40 million. Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
Look for Shares of MannKind to Potentially Rebound after Yesterday's 1.87% Sell Off
Comtex SmarTrend(R) - Mon Apr 14, 5:31PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.15 to a high of $6.58. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $6.31 on volume of 9.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MannKind's Overly-Optimisitic Investors
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:47PM CDT
Last week, MannKind announced that the Food and Drug Administration was delaying a decision about whether to approve its inhaled insulin Afezza by three months. Investors seemed surprised, with shares falling 8% on Monday, although it made all...
Critical Alerts For Walt Disney, Walgreen, BioMarin Pharmaceuticals, Canadian Solar, and MannKind Released By InvestorsObserver
PR Newswire - Mon Apr 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DIS, WAG, BMRN, CSIQ, and MNKD.
